Effect of anti-vascular endothelial growth factor antibody during early fetal development in rats

Basit Öğe Kaydı
dc.authoridKaygusuz, Ikbal/0000-0002-5635-505X|YENIDUNYA, SIBEL/0000-0002-5645-6301
dc.contributor.authorKaygusuz, Ikbal
dc.contributor.authorEser, Ayla
dc.contributor.authorGumus, Ilknur Inegol
dc.contributor.authorKosus, Aydin
dc.contributor.authorYenidunya, Sibel
dc.contributor.authorNamuslu, Mehmet
dc.contributor.authorKafali, Hasan
dc.date.accessioned2025-10-24T18:09:45Z
dc.date.available2025-10-24T18:09:45Z
dc.date.issued2014
dc.departmentMalatya Turgut Özal Üniversitesi
dc.description.abstractObjective: To examine the effect of anti-vascular endothelial growth factor (VEGF) antibody Bevacizumab during early fetal development in rats. Methods: Presumed-pregnant rats received single intraperitoneal injection of Bevacizumab (0-20 mg/kg) on gestational day (GD) 3, 7, and 14 (n = 2 rats/group). After Study 1 (dose range finding study), Study 2 performed with intraperitoneal 20 mg/kg bevacizumab or saline on GD 7 (n = 6 rats/group including the Study 1). Blood samples were collected 3 and 7 d after the injection. Uterus and ovarian tissues were obtained 7 d after the injection. Number of gestational sacs (GS), size of GS and fetus, serum rat beta chorionic gonadotropin (beta-CG), and platelet endothelial cell adhesion molecule (PECAM) for immunohistochemical assessment of angiogenesis were evaluated. Results: Number of GS, size of GS, and fetus were lower in the study group than the control group. Serum rat beta-CG levels were significantly increased in the control group and significantly decreased in the study group. Staining densities for PECAM in vascular structures in both corpus luteum and placenta were lower in the study group than the control group. Conclusion: Anti-VEGF antibody has an inhibitory effect on pregnancy development and caused litter death.
dc.identifier.doi10.3109/14767058.2013.879645
dc.identifier.endpage1748
dc.identifier.issn1476-7058
dc.identifier.issn1476-4954
dc.identifier.issue17
dc.identifier.pmid24397777
dc.identifier.scopus2-s2.0-84911884221
dc.identifier.scopusqualityQ1
dc.identifier.startpage1744
dc.identifier.urihttps://doi.org/10.3109/14767058.2013.879645
dc.identifier.urihttps://hdl.handle.net/20.500.12899/3802
dc.identifier.volume27
dc.identifier.wosWOS:000344080600005
dc.identifier.wosqualityQ3
dc.indekslendigikaynakWeb of Science
dc.indekslendigikaynakScopus
dc.indekslendigikaynakPubMed
dc.language.isoen
dc.publisherInforma Healthcare
dc.relation.ispartofJournal Of Maternal-Fetal & Neonatal Medicine
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanı
dc.rightsinfo:eu-repo/semantics/closedAccess
dc.snmzKA_20251023
dc.subjectAnti-angiogenic agent; anti-VEGF antibody; bevacizumab; fetal development; rat
dc.titleEffect of anti-vascular endothelial growth factor antibody during early fetal development in rats
dc.typeArticle

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayınlar Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu